Effects of direct‐acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real‐life Italian experience. Issue 5 (11th July 2022)

• Record Type: Journal Article
• Authors: Dalbeni, Andrea; Villani, Rosanna; Bevilacqua, Michele; Sacco, Federica; Faccincani, Diego; Cattazzo, Filippo; Cavallone, Francesco; Mantovani, Anna; Ceruti, Vittoria; Ieluzzi, Donatella; Paon, Veronica; Mantovani, Alessandro; Serviddio, Gaetano; Sacerdoti, David
• Is Part Of: Journal of digestive diseases. Volume 23:Issue 5/6(2022)
• Page Start: 324
• Page End: 330
• Publication Date: 2022-07-11
• Subjects: cardiovascular risk factors -- direct‐acting antiviral agents -- glucose profile -- hepatitis C virus -- lipid profile -- type 2 diabetes mellitus; Digestive organs -- Diseases -- Periodicals; Gastroenterology -- Periodicals; 616.3
• DOI: 10.1111/1751-2980.13103
• Languages: English
• ISSNs: 1751-2972

Abstract

Abstract : Objectives: Hepatitis C virus (HCV) infection is associated with an increased risk of type 2 diabetes mellitus (T2DM) and cardiovascular diseases. The impact of HCV eradication on the metabolic profile in diabetic patients treated with direct‐acting antiviral agents (DAAs) is not well defined. The aim of our study was to evaluate the effects of DAAs on a lipid and glucose profile in a cohort of diabetic patients with different liver fibrotic stages. Methods: T2DM patients with active HCV infection were consecutively enrolled in this prospective trial. Glycolipidic status was assessed, before starting DAA treatment (T0) and at 12 months after the beginning of treatment (T1). Liver fibrotic stage was assessed by FibroScan. Results: In all, 131 patients were enrolled and all of them achieved a sustained virologic response. At baseline, no significant differences were found in lipid and glucose profiles in subgroup analysis by liver fibrosis, HCV genotype, and cardiovascular risk factors. At T1, total cholesterol and low‐density lipoprotein cholesterol, but not triglycerides, significantly increased irrespective of liver fibrotic stage and baseline anthropometric and clinical profiles, while glycated hemoglobin significantly decreased only in F4 patients. Conclusions: HCV eradication in diabetic patients is associated with a worsening lipid profile that could impact future cardiovascular risk. A careful global monitoring of cardiovascular risk factors in all diabetic patients after HCV eradication is needed. Abstract : Hepatitis C virus (HCV) infection is associated with an increased risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. Treatment with direct‐acting antiviral agents (DAAs) showed an improvement in liver profile but worsening lipid composition in T2DM patients. Glycometabolic control was improved only in patients with advanced fibrosis. A careful monitoring of cardiovascular risk factors in all diabetic patients before and after HCV eradication is needed.